Kathryn Josephs

Dana-Farber Cancer Institute

Boston, Massachusetts - 02115

CLINICAL TRIALS 1
CONDITIONS1
INTERVENTIONS3
SINCE2009

A Study of Trastuzumab-MCC-DM1 Paclitaxel and Pertuzumab in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer

August 2009 -

Breast Neoplasms

Paclitaxel

Trastuzumab-Mcc-Dm1

Pertuzumab

Learn about TrialX Patient Recruitment services

Massimo Loda, MD

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute

Suzanne Shusterman

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Childrens Hospital Boston, Dana-Farber Cancer Institute. Children's Hospital Boston

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Dana-Farber Cancer Institute Dana Farber / Brigham and Women's Cancer Center Dana-Farber Cancer Institute, Center for Neuro-Oncology Dana-Farber Cancer Instiute

Lewis B. Silverman, MD

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Dana-Farber Cancer Institute and Children's Hospital Dana Faber Cancer Institute, Children's Hospital, Dept. of Pediatric Oncology Children's Hospital Boston Dana-Farber Cancer Institute

Kathryn Josephs

Dana-Farber Cancer Institute

Massimo Loda, MD

Suzanne Shusterman

Patrick Y. Wen, MD

Lewis B. Silverman, MD

Kay Kehoe, Coordinator

Jennifer Brown, MD

Rachel A. Freedman

Edwin P. Alyea, MD

F. Stephen Hodi, MD

Beth A. Overmoyer, MD, FACP